Frankfurt - Delayed Quote EUR

Wave Life Sciences Ltd. (1U5.F)

4.8600

-0.3400

(-6.54%)

At close: April 17 at 9:17:15 AM GMT+2

Will Wave Life Sciences (NASDAQ:WVE) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 4 days ago

WVE
The Zacks Analyst Blog Highlights Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics

Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics are part of the Zacks top Analyst Blog

Zacks 19 days ago

CRSP

WVE

TWST
Promising Genomics & Synthetic Biology Stocks to Consider in 2025

Investors interested in the Genomics and Synthetic Biology theme should consider these stocks: Twist Bioscience Corporation, Wave Life Sciences, and CRISPR Therapeutics AG.

Zacks 22 days ago

CRSP

WVE
Wave Life Sciences unveils Phase II data for DMD therapy, WVE-N531

The company is targeting 2026 for a US filing for the drug.

Clinical Trials Arena 23 days ago

WVE

GLDAF
Wave Life Sciences (WVE) Stock Jumps 6.1%: Will It Continue to Soar?

Wave Life Sciences (WVE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks 23 days ago

WVE

AGIO
Wave Life Sciences Reports 'Positive' Data for Prospective Duchenne Treatment; Shares Up Pre-Bell

Wave Life Sciences (WVE) shares were higher premarket Wednesday after the company reported "positive

PREMIUM
MT Newswires 24 days ago

WVE
Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531

Statistically significant and clinically meaningful improvement of 3.8 seconds in Time-to-Rise vs. natural history with largest effect observed relative to any approved dystrophin restoration therapy at 48 weeks; additional functional benefits observed in other outcome measures including NSAA First-ever demonstration of substantial improvements in muscle health with exon skipping – statistically significant reduction in fibrosis driven by decreases in inflammation and necrosis, coupled with tran

GlobeNewswire 24 days ago

WVE
Adma Biologics (ADMA) Surges 10.2%: Is This an Indication of Further Gains?

Adma Biologics (ADMA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks 30 days ago

ADMA

WVE
Wave Life Sciences Full Year 2024 Earnings: Beats Expectations

Wave Life Sciences ( NASDAQ:WVE ) Full Year 2024 Results Key Financial Results Revenue: US$108.3m (down 4.4% from FY...

Simply Wall St. last month

WVE
WAVE Life Sciences Ltd (WVE) Q4 2024 Earnings Call Highlights: Revenue Surge Amidst Clinical ...

WAVE Life Sciences Ltd (WVE) reports a strong Q4 with significant revenue growth and promising clinical progress, despite full-year financial challenges.

GuruFocus.com last month

WVE
Wave Life Sciences: Q4 Earnings Snapshot

SINGAPORE (AP) — Wave Life Sciences Pte. Ltd. (WVE) on Tuesday reported fourth-quarter profit of $29.3 million. On a per-share basis, the Singapore-based company said it had profit of 17 cents.

Associated Press Finance last month

WVE
Wave Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Dosing underway in INLIGHT trial of WVE-007 in obesity with clinical data expected in 2H 2025; enrollment complete in first single dose cohort Multi-dosing ongoing in 200 mg cohort of RestorAATion-2 clinical trial of WVE-006 in AATD with data expected in 2025; second single dose cohort initiated at 400 mg On track to deliver FORWARD-53 48-week data in DMD and feedback from regulators in 1Q 2025 IND submission expected 2H 2025 for potentially registrational WVE-003 Phase 2/3 study in HD with caud

GlobeNewswire last month

WVE
Will Foghorn Therapeutics Inc. (FHTX) Report Negative Q4 Earnings? What You Should Know

Foghorn Therapeutics (FHTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks last month

FHTX

WVE
Wave Life Sciences Fourth Quarter and Full Year 2024 Financial Results Scheduled for March 4, 2025

CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Tuesday, March 4, 2025, to review the company’s fourth quarter and full year 2024 financial results and provide business updates. The webcast and conference call may be accessed by visiting “Investor Events” on the invest

GlobeNewswire last month

WVE
What Makes Wave Life Sciences Ltd. (WVE) an Investment Bet?

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter. The Fund performed roughly in line with the Benchmark, during a challenging quarter for the larger health care industry. A copy of the letter can be downloaded here. The fund declined 9.58% (Institutional Shares) in the quarter compared […]

Insider Monkey last month

WVE
Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity

WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new approach for healthy, sustainable weight loss (fat loss with muscle preservation) Proof-of-concept clinical data from INLIGHT are expected in 2025 CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced cli

GlobeNewswire 2 months ago

WVE
Wave Life Sciences (NASDAQ:WVE) shareholders have earned a 69% CAGR over the last three years

Wave Life Sciences Ltd. ( NASDAQ:WVE ) shareholders might be concerned after seeing the share price drop 14% in the...

Simply Wall St. 2 months ago

WVE
Is Wave Life Sciences (WVE) the Top Small Cap Stock to Buy with the Highest Upside Potential?

We recently published a list of the Top 10 Small Cap Stocks to Buy with the Highest Upside Potential. In this article, we are going to take a look at where Wave Life Sciences Ltd. (NASDAQ:WVE) stands against other top small cap stocks to buy with the highest upside potential. What Would 2025 Look Like […]

Insider Monkey 3 months ago

WVE
Wave Life Sciences Highlights Strategic Priorities and Expected 2025 Milestones Ahead of J.P. Morgan Presentation

Entering 2025 having demonstrated rapid translation of genetic insights to positive clinical data; advancing clinically validated and multi-modal pipeline with the potential to treat well over 100 million patients CTAs submitted for Phase 1 INLIGHT clinical trial of WVE-007, a novel, long-acting, muscle-sparing GalNAc-siRNA approach for obesity targeting INHBE grounded in human genetics; proof-of-concept clinical data expected in 2025 Pioneering entirely new therapeutic field of RNA editing and

GlobeNewswire 3 months ago

WVE
Is Wave Life Sciences Ltd. (WVE) the Best Growth Stock to Buy Now Under $25?

We recently compiled a list of the 12 Best Growth Stocks Under $25 to Buy Now. In this article, we are going to take a look at where Wave Life Sciences Ltd. (NASDAQ:WVE) stands against the other growth stocks. AI is the Most Defining Theme of 2025, Says Expert Most experts agree that the AI wave […]

Insider Monkey 3 months ago

WVE

Performance Overview

Return	1U5.F	S&P 500 (^GSPC)
YTD	-60.16%	-10.18%
1-Year	-1.22%	+5.19%
3-Year	+145.52%	+20.26%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Wave Life Sciences Ltd. (1U5.F)

Will Wave Life Sciences (NASDAQ:WVE) Spend Its Cash Wisely?

The Zacks Analyst Blog Highlights Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics

Promising Genomics & Synthetic Biology Stocks to Consider in 2025

Wave Life Sciences unveils Phase II data for DMD therapy, WVE-N531

Wave Life Sciences (WVE) Stock Jumps 6.1%: Will It Continue to Soar?

Wave Life Sciences Reports 'Positive' Data for Prospective Duchenne Treatment; Shares Up Pre-Bell

Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531

Adma Biologics (ADMA) Surges 10.2%: Is This an Indication of Further Gains?

Wave Life Sciences Full Year 2024 Earnings: Beats Expectations

WAVE Life Sciences Ltd (WVE) Q4 2024 Earnings Call Highlights: Revenue Surge Amidst Clinical ...

Wave Life Sciences: Q4 Earnings Snapshot

Wave Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Will Foghorn Therapeutics Inc. (FHTX) Report Negative Q4 Earnings? What You Should Know

Wave Life Sciences Fourth Quarter and Full Year 2024 Financial Results Scheduled for March 4, 2025

What Makes Wave Life Sciences Ltd. (WVE) an Investment Bet?

Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity

Wave Life Sciences (NASDAQ:WVE) shareholders have earned a 69% CAGR over the last three years

Is Wave Life Sciences (WVE) the Top Small Cap Stock to Buy with the Highest Upside Potential?

Wave Life Sciences Highlights Strategic Priorities and Expected 2025 Milestones Ahead of J.P. Morgan Presentation

Is Wave Life Sciences Ltd. (WVE) the Best Growth Stock to Buy Now Under $25?

Performance Overview